Stealth BioTherapeutics (NASDAQ:MITO) Rating Lowered to Sell at Zacks Investment Research

Share on StockTwits

Stealth BioTherapeutics (NASDAQ:MITO) was downgraded by Zacks Investment Research from a “buy” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports.

According to Zacks, “Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company’s product pipeline includes Elamipretide, SBT-20 and SBT-272 which are in clinical stage. Stealth BioTherapeutics Corp is based in Newton, Massachusetts. “

Several other equities research analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Stealth BioTherapeutics in a research note on Tuesday, October 8th. Cantor Fitzgerald initiated coverage on Stealth BioTherapeutics in a research note on Friday, September 27th. They issued an “overweight” rating and a $18.00 price objective for the company. One analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $22.43.

NASDAQ MITO opened at $6.37 on Wednesday. The stock has a market capitalization of $239.96 million and a PE ratio of -4.52. The business has a 50 day simple moving average of $7.10 and a two-hundred day simple moving average of $11.35. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.13 and a quick ratio of 2.13. Stealth BioTherapeutics has a 1-year low of $4.97 and a 1-year high of $20.99.

Stealth BioTherapeutics (NASDAQ:MITO) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.04. On average, analysts anticipate that Stealth BioTherapeutics will post -0.14 EPS for the current fiscal year.

About Stealth BioTherapeutics

Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction. Its lead product candidate, Elamipretide, has the potential to treat rare genetic and common age-related mitochondrial diseases.

Recommended Story: How does a 12b-1 fee affect fund performance?

Get a free copy of the Zacks research report on Stealth BioTherapeutics (MITO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Stealth BioTherapeutics (NASDAQ:MITO)

Receive News & Ratings for Stealth BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stealth BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.